Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.

BACKGROUND: Several clinical trials have shown that nirsevimab, an antibody targeting the respiratory syncytial virus (RSV), reduces RSV bronchiolitis requiring admission. In 2023-2024, Catalonia and Andorra adopted immunization strategies for children <6 months and those born during the epidemic season. This study evaluates the effectiveness of nirsevimab in preventing hospitalizations from RSV bronchiolitis. METHODS: In the epidemic season of 2023-2024, a test-negative case-control study was conducted in three hospitals from Catalonia and Andorra. Patients <12 months old admitted with bronchiolitis and tested for RSV using molecular microbiology tests were included. The effectiveness in preventing RSV bronchiolitis hospitalization and severe disease was estimated using multivariate models. Comparisons between immunized, non-immunized, and non-eligible patients were made in prospectively collected epidemiological, clinical, and microbiological variables. RESULTS: Two hundred thirty-four patients were included. RSV was detected in 141/234 (60.2%), being less common in the immunized group (37% vs 75%, p < .001). The rate of immunized patients among those eligible was 59.7%. The estimated effectiveness for RSV-associated lower respiratory tract infection was 81.0% (95% confidence interval: 60.9-90.7), and for preventing severe disease (the need for NIV/CMV), 85.6% (41.7-96.4%). No significant differences by immunization status were observed in patients with RSV concerning viral coinfections, the need for NIV/CMV or length of hospital stay. CONCLUSIONS: This study provides real-world evidence of the effectiveness of nirsevimab in preventing RSV-lower respiratory tract infection hospitalization and severe disease in infants during their first RSV season following a systematic immunization program. Immunized patients did not exhibit a higher rate of viral coinfections nor differences in clinical severity once admitted.

Addressing global health disparities in the management of RSV infection in infants and children: Strategies for preventing bronchiolitis and post-bronchiolitis recurrent wheezing.

Background: The topic of equitable access to health care and its impact on exacerbating worldwide inequities in child health not only strikes at the heart of our health-care delivery systems but also deeply resonates with our collective social consciences. Nowhere is this better seen on a global scale than in the burden of illness caused by respiratory syncytial virus (RSV) infection, which extracts the most severe morbidity and mortality in infants and children in low- and middle-income countries (LMIC). This report addresses global health disparities that exist in the management of RSV infection in infants and children, and offers strategies for preventing bronchiolitis and postbronchiolitis recurrent wheezing in LMICs. Methods: A systematic literature review was conducted across the PubMed data bases of RSV infection and the socioeconomic impact of bronchiolitis and postbronchiolitis recurrent wheezing in LMICs. Results: The results of the present study address the many issues that deal with the question if prevention of RSV bronchiolitis can mitigate recurrent wheezing episodes and links RSV risks, downstream effects, prevention, malnutrition, and socioeconomic restraints of developing countries with a call for possible global action. Conclusion: The present study stresses the importance of considering the linkage between malnutrition and disease susceptibility because of the known relationships between undernutrition and greater vulnerability to infectious diseases, including RSV infection. These complex interactions between infectious disease and undernutrition also raise issues on the longer-term sequelae of postbronchiolitis recurrent wheezing. This prompts a discussion on whether industrialized countries should prioritize the provision of newly developed monoclonal antibodies and RSV vaccines to LMICs or whether vital nutritional needs should be a first focus. The resolution of these issues will require research and greater international discourse.

Bronchiolitis recovery and the use of High Efficiency Particulate Air (HEPA) Filters (The BREATHE Study): study protocol for a multi-center, parallel, double-blind, randomized controlled clinical trial.

BACKGROUND: Acute viral bronchiolitis is the most common reason for hospitalization of infants in the USA. Infants hospitalized for bronchiolitis are at high risk for recurrent respiratory symptoms and wheeze in the subsequent year, and longer-term adverse respiratory outcomes such as persistent childhood asthma. There are no effective secondary prevention strategies. Multiple factors, including air pollutant exposure, contribute to risk of adverse respiratory outcomes in these infants. Improvement in indoor air quality following hospitalization for bronchiolitis may be a prevention opportunity to reduce symptom burden. Use of stand-alone high efficiency particulate air (HEPA) filtration units is a simple method to reduce particulate matter ≤ 2.5 µm in diameter (PM2.5), a common component of household air pollution that is strongly linked to health effects. METHODS: BREATHE is a multi-center, parallel, double-blind, randomized controlled clinical trial. Two hundred twenty-eight children < 12 months of age hospitalized for the first time with bronchiolitis will participate. Children will be randomized 1:1 to receive a 24-week home intervention with filtration units containing HEPA and carbon filters (in the child's sleep space and a common room) or to a control group with units that do not contain HEPA and carbon filters. The primary objective is to determine if use of HEPA filtration units reduces respiratory symptom burden for 24 weeks compared to use of control units. Secondary objectives are to assess the efficacy of the HEPA intervention relative to control on (1) number of unscheduled healthcare visits for respiratory complaints, (2) child quality of life, and (3) average PM2.5 levels in the home. DISCUSSION: We propose to test the use of HEPA filtration to improve indoor air quality as a strategy to reduce post-bronchiolitis respiratory symptom burden in at-risk infants with severe bronchiolitis. If the intervention proves successful, this trial will support use of HEPA filtration for children with bronchiolitis to reduce respiratory symptom burden following hospitalization. TRIAL REGISTRATION: NCT05615870. Registered on November 14, 2022.

Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and associated with most bronchiolitis- and pneumonia-related hospitalizations. A new preventive monoclonal antibody (MAb), nirsevimab, has been launched in the United States, Luxembourg, and France, and was recently approved to be given in a population-based manner throughout Spain. This study aimed to have a first pre-immunization insight into the Spanish parental knowledge about bronchiolitis, RSV, and nirsevimab immunization. Parents in Murcia with children <2 years of age up to the date of September 1, 2023, were selected to complete a questionnaire. The primary endpoint was the parental knowledge about bronchiolitis, RSV, and nirsevimab. A total of 3,217 responses were analyzed. The majority (95.8%) were aware of bronchiolitis. Meanwhile, 46.6% of the respondents knew about RSV, most of them only after the first child's birth. Information about RSV or bronchiolitis was mainly obtained from family members, with only 4.8% reporting having been informed by Health care Professionals (HCPs). Only 11.2% of respondents were aware of nirsevimab. Nonetheless, these were not entirely satisfied with the information received (score of 3.3 out of 5) and shared that HCPs should be the primary source of information. The present survey then highlights the need for better and more efficient educational strategies directed to all parents/legal guardians. It also sheds some light on the different factors that should be considered to improve awareness of RSV immunization to decrease its burden in Spain and beyond.

Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).

BACKGROUND: In Catalonia, infants under 6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse nirsevimab's effectiveness across primary and hospital care outcomes. METHODS: Retrospective cohort study from 1 October 2023 to 31 January 2024, including all infants born between April and September 2023. We established two cohorts based on nirsevimab administration (immunised and non-immunised). We followed individuals until the earliest moment of an outcome-RSV infection, primary care attended bronchiolitis and pneumonia, hospital emergency visits due to bronchiolitis, hospital admission or intensive care unit (ICU) admission due to RSV bronchiolitis-death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate HRs and their 95% CIs. RESULTS: Among 26 525 infants, a dose of nirsevimab led to an adjusted HR for hospital admission due to RSV bronchiolitis of 0.124 (95% CI: 0.086 to 0.179) and an adjusted HR for ICU admission of 0.099 (95% CI: 0.041 to 0.237). Additionally, the adjusted HRs observed for emergency visits were 0.446 (95% CI: 0.385 to 0.516) and 0.393 (95% CI: 0.203 to 0.758) for viral pneumonia, 0.519 (95% CI: 0.467 to 0.576) for bronchiolitis attended in primary care and 0.311 (95% CI: 0.200 to 0.483) for RSV infection. CONCLUSION: We demonstrated nirsevimab's effectiveness with reductions of 87.6% and 90.1% in hospital and ICU admissions, respectively. These findings offer crucial guidance for public health authorities in implementing RSV immunisation campaigns.

Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.

BACKGROUND: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis. METHODS: Population-based real-world data from primary care and hospitalizations were considered. RSV bronchiolitis dynamics in absence of these immunization scenarios were explained by a multivariate age-structured Bayesian model. Then, the potential impact was simulated under different assumptions including the most recent clinical trial data. Differences in endpoints, populations, and timeframes between trials make the two products' efficacy difficult to compare. RESULTS: A seasonal with catch-up program, assuming a constant effectiveness of 79.5 % during the first 5 months followed by a linear decay to 0 by month 10 with nirsevimab, would prevent between 5121 and 8846 RSV bronchiolitis per 100,000 infants-years. Assuming 77.3 % effectiveness with the same decay, between 976 and 1686 RSV-hospitalizations per 100,000 infants-years could be prevented depending on the uptake. A year-round maternal immunization program, with 51 % of effectiveness during the first 6 months followed by a linear decay to 0 by month 10 would prevent between 3246 and 5606 RSV bronchiolitis cases per 100,000 infants-years. Assuming 56.9 % effectiveness with the same decay, between 713 and 1231 RSV-hospitalizations per 100,000 infants-years could be prevented. CONCLUSIONS: Our results suggest that each strategy would effectively reduce RSV-bronchiolitis.

Identifying the impact of non-pharmaceutical interventions on RSV transmission in a single-centre observational study.

During the COVID-19 pandemic, the introduction of non-pharmaceutical interventions (NPIs) resulted in an unprecedented reduction in the transmission of the respiratory syncytial virus (RSV), the predominant cause of bronchiolitis. As NPIs were eased, it was speculated that RSV transmission would return with an increase in the severity of bronchiolitis. In a large tertiary hospital, a dramatic reduction in the incidence of bronchiolitis was seen during the COVID-19 pandemic. The easing of NPIs correlated with an increase in RSV transmission particularly in the community; however, there was no evidence of an increase in the severity of bronchiolitis.

Vacunar a la embarazada puede prevenir la bronquiolitis por virus respiratorio sincitial en el lactante / Vaccinating pregnant women can prevent respiratory syncytial virus bronchiolitis in infants

Conclusiones de los autores del estudio: la vacuna de proteína F prefusión contra el virus respiratorio sincitial, administrada a embarazadas en el último trimestre de embarazo, previene de infecciones respiratorias graves por dicho virus en sus lactantes, sin efectos adversos de importancia. Comentario de los revisores: la vacuna parece eficaz y segura, aunque las estimaciones de eficacia son imprecisas. Constituye una opción preventiva alternativa a la administración de nirsevimab en el recién nacido, con expectativas de impacto equiparables. (AU)

Authors´ conclusions: prefusion F protein vaccine against respiratory syncytial virus administered to pregnant women in the last trimester of pregnancy prevents this virus severe respiratory infections in their infants, without important adverse effects. Reviewers´ commentary: the vaccine appears effective and safe, although its efficacy estimates are imprecise. It constitutes an alternative preventive option to the administration of nirsevimab in the newborn, with comparable impact expectations. (AU)

Diseño y estudio de fiabilidad del cuestionario de conocimientos, aptitudes y prácticas de progenitores sobre prevención y abordaje de bronquiolitis aguda en población pediátrica menor de dos años / Design and reliability study of a parental knowledge, attitude, and practice questionnaire on prevention and management of acute bronchiolitis of children under two years of age

Fundamento: La bronquiolitis aguda es la causa más común de hospitalización en el primer año de vida. La prevención primaria y el cuidado de soporte son fundamentales. El objetivo de este estudio es crear un cuestionario para progenitores sobre la prevención y abordaje domiciliario de la bronquiolitis aguda, y estudiar sus propiedades psicométricas. Material y métodos: El diseño del cuestionario se basó en una búsqueda de la bibliografía sobre las estrategias de prevención y factores de riesgo de la bronquiolitis. Un comité de expertos evaluó su contenido mediante el índice de validez de contenido (IVC), y la consistencia interna (fiabilidad) se evaluó mediante alfa de Cronbach (α). Resultados: Se obtuvo un cuestionario de 26 ítems dividido en cuatro dimensiones (Factores de riesgo, Signos y síntomas, Prevención, Cuidados y soporte farmacológico) cuya puntuación normalizada oscila entre -50 y +50; se consideró existencia de buenos conocimientos, actitudes y hábitos si >0. El comité de expertos valoró todos los ítems con IVC >0,80, siendo el IVC global 0,90. La consistencia interna global fue α=0,77, con diferencias entre las puntuaciones individuales de las diferentes dimensiones del cuestionario. Conclusiones: El Cuestionario de conocimientos, aptitudes y prácticas para padres sobre prevención y abordaje domiciliario de la bronquiolitis aguda obtuvo una validez de contenido excelente tras la puntuación del comité de expertos, así como una consistencia interna aceptable. Puede ser una herramienta útil para reforzar aquellas medidas que los progenitores desconocen o no aplican.(AU)

Background: Acute bronchiolitis is the most common cause of hospitalization in the first year of life. Primary prevention and supportive care are key. Here, we aimed to design and assess the psychometric properties of a parent-focused questionnaire on prevention and management of acute bronchiolitis at home in children under two years of age. Methodology: For the design of the questionnaire, we conducted a literature search on prevention strategies and risk factors for bronchiolitis. An expert committee evaluated the content of the new questionnaire using the Content Validity Index and estimated the internal consistency reliability with Cronbach’s alpha. Results: A 26-item questionnaire divided into four dimensions (Risk factors, Signs and symptoms, Prevention, Care and pharmacological support) was created. The normalized score fell in the range between -50 and +50; a positive score was interpreted as presence of good knowledge, attitudes, and habits. Each of the 26 items obtained a Content Validity Index score > 0.80 and the global score was 0.90. The global internal consistency was α = 0.77, with differences between individual scores of the different dimensions of the questionnaire.Conclusion: The Parental knowledge, attitude, and practice questionnaire on prevention and management of acute bronchiolitis at home obtained an excellent Content Validity Index score by the expert committee and an acceptable internal consistency. Our questionnaire may reinforce the weak knowledge areas regarding the measures to apply.(AU)

Apneas en lactantes con bronquiolitis: incidencia y factores de riesgo para un modelo de predicción / Apnoea in infants with bronchiolitis: Incidence and risk factors for a prediction model

Introducción: La presencia de apneas en la bronquiolitis aguda (BA) varía según las series entre el 1,2 y el 28,8%, y es una de sus complicaciones más temibles. Nuestro objetivo es conocer la incidencia de apneas en pacientes ingresados con diagnóstico de BA y definir sus factores de riesgo asociados para construir un modelo de predicción. Pacientes y método: Estudio observacional retrospectivo de los últimos 5 años de pacientes ingresados en un hospital terciario con diagnóstico de BA según los criterios clásicos. Se recogieron la frecuencia de apneas y las variables clínicas relacionadas, para encontrar factores de riesgo en un modelo de regresión logística binaria para la predicción de apneas. Para evaluar el modelo se elaboró una curva ROC. Resultados: De 1.197 casos, se registró apnea durante el ingreso en 53 (4,4%). Los factores de riesgo incluidos en la ecuación fueron: sexo femenino (OR 0,6; IC del 95%: 0,27-1,37), cesárea (OR: 3,44; IC del 95%: 1,5-7,7), edad posmenstrual ≤ 43 semanas (OR: 6,62; IC del 95%: 2,38-18,7), fiebre (OR: 0,33; IC del 95%: 0,09-1,97), bajo peso al ingreso (OR: 3,06; IC del 95%: 1,23-7,67), apneas antes del ingreso observada por los cuidadores (OR: 5,93; IC del 95%: 2,64-13,3) y sobreinfección bacteriana grave (OR: 3,98; IC del 95%: 1,68-9,46). La sensibilidad y la especificidad óptima del modelo en la curva ROC fueron de 0,842 y 0,846, respectivamente (p < 0,001). Conclusiones: La incidencia de apneas durante el ingreso fue de 4,4 por cada 100 ingresos de BA y año. La ecuación del modelo de predicción estimado puede ser de ayuda al clínico para clasificar a los pacientes con mayor riesgo de apnea durante el ingreso en la BA (AU)

Introduction: The presence of apnoea in acute bronchiolitis (AB) varies between 1.2% and 28.8%, depending on the series, and is one of its most fearsome complications. The aim of this study is to determine the incidence of apnoea in hospitalised patients diagnosed with AB, and to define their associated risk factors in order to construct a prediction model. Patients and method: A retrospective observational study of patients admitted to a tertiary hospital in the last 5 years with a diagnosis of AB, according to the classic criteria. Data was collected on the frequency of apnoea and related clinical variables to find risk factors in a binary logistic regression model for the prediction of apnoea. A ROC curve was developed with the model. Results: Apnoea was recorded during the admission of 53 (4.4%) patients out of a total 1,197 cases found. The risk factors included in the equation were: Female (OR 0.6, 95% CI: 0.27-1.37), Caesarean delivery (OR: 3.44, 95% CI: 1.5-7.7), Postmenstrual age ≤43 weeks (OR: 6.62, 95% CI: 2.38-18.7), Fever (OR: 0.33, 95% CI: 0.09-1.97), Low birth weight (OR: 5.93, 95% CI: 2.23-7.67), Apnoea observed by caregivers before admission (OR: 5.93, 95% CI: 2.64-13.3), and severe bacterial infection (OR: 3.98, 95% CI: 1.68-9.46). The optimal sensitivity and specificity of the model in the ROC curve was 0.842 and 0.846, respectively (P < .001). Conclusions: The incidence of apnoea during admission was 4.4 per 100 admissions of AB and year. The estimated prediction model equation may be of help to the clinician in order to classify patients with increased risk of apnoea during admission due to AB (AU)

Predicción de la evolución de la bronquiolitis por virus respiratorio sincitial en lactantes menores de 6 meses / Prediction of severe course in infants with RSV Bronchiolitis under 6 months. Spain

Fundamentos. La necesidad de ventilación mecánica (VM) en la bronquiolitis aguda por el virus respiratorio sincitial (VRS) varía según las series entre el 6 y el 18 %. Nuestro objetivo fue conocer los ingresos en la unidad de cuidados intensivos para VM de pacientes con bronquiolitis aguda menores de 6 meses y definir los factores de riesgo con el fin de construir un modelo de predicción. Método. Estudio retrospectivo de pacientes menores de 6 meses ingresados por bronquiolitis aguda por VRS entre los periodos 1 de abril de 2010 y 31 de marzo de 2015. La variable principal fue el ingreso en la unidad de cuidados intensivos pediátricos para ventilación mecánica. Además, se recogieron variables clínicas relacionadas para hallar factores de riesgo en un modelo de regresión logística binaria. Con el modelo se elaboró una curva ROC y se identificó un punto óptimo de corte. Resultados. De 695 casos, precisaron VM en unidad pediátrica de cuidados intensivos 56 (8,1%). Los factores de riesgo) incluidos en la ecuación fueron: 1. Sexo varón (OR: 4,27) 2. Edad postmenstrual (OR:0,76) 3. Peso al ingreso 37 semanas OR (0,32). El área bajo la curva, sensibilidad y especificidad fueron 0,943; 0,84 y 0,93 respectivamente. Conclusiones. Los ingresos en UCIP para VM fueron 8,1 por cada 100 lactantes sanos hospitalizados por BA y año. La ecuación elaborada del modelo de predicción puede ser de ayuda para predecir los pacientes con mayor riesgo de evolución grave (AU)

Background. The need for mechanical ventilation (MV) in acute bronchiolitis (AB) by respiratory syncytial virus (RSV) varies depending on the series (6-18%). Our goal is to determine the admissions to PICU for MV in patients under 6 months with AB and define the risk factors for building a prediction model. Methods. Retrospective study of patients younger than 6 months admitted by BA-VRS between the periods April 1, 2010 and March 31, 2015 was made. The primary variable was the admission to PICU for MV. Related addition, to find risk factors in a model of binary logistic regression clinical variables were collected. A ROC curve model was developed and optimal cutoff point was identified. Results. In 695 cases, the need of MV in the PICU was 56 (8.1%). Risk factors included in the equation were: 1. male sex (OR 4.27) 2. postmenstrual age (OR: 0.76) 3. Weight income 37 weeks OR (0.32). The area under the curve, sensitivity and specificity were 0.943, 0.84 and 0.93 respectively. Conclusions. The PICU admission for MV was 8.1 in every 100 healthy infants hospitalized for AB and year. The prediction model equation can help to predict patients at increased risk of severe evolution (AU)

Comprobemos también si las guías de práctica clínica se usan correctamente y funcionan. Respuesta de los autores / Let's also check if clinical practice guidelines are correctly used and if they do work. Authors reply

No disponible

Prevenção de Infecções pelo Vírus Sincicial Respiratório (VSR): uso do palivizumabe / Respiratory Syncytial Vírus (RSV) infection prevention: palivizumab use

Introdução: o vírus sincicial respiratório (VSR) pode causar quadros graves de bronquiolites e pneumonias, principalmente em grupos de risco como prematuros, cardiopatas e portadores de pneumopatias. O palivizumabe (PVZ) trouxe grande avanço na prevenção dessa doença e, devido ao alto custo, a Secretaria de Estado da Saúde de Minas Gerais (SES-MG) disponibiliza o produto aos grupos de alto risco. Objetivo: orientar os pediatras quanto à prevenção da infecção pelo VSR com orientações práticas sobre a prescrição do PVZ em MG. Métodos: são apresentados os critérios de inclusão para o uso dessa medicação em MG segundo portaria do Ministério da Saúde de 2013, como também os procedimentos adequados para a prescrição e fornecimento segundo normas da SES-MG. Resultados e conclusões: o conhecimento sobre o uso do PVZ para a prevenção do VSR e dos fluxos adequados para a prescrição e aplicação dessa medicação é fundamental para a prevenção da bronquiolite, portanto, deve ser amplamente divulgado entre os pediatras. Dessa forma, poderá ocorrer a redução dos casos graves, diminuindo a prevalência de sequelas e óbitos por essa doença.(AU)

Introduction: Respiratory Syncytial Vírus (RSV) can cause severe cases of bronchiolitis and pneumonia especially in risk groups such as premature neonates, cardiac patients and children with lung disease. Palivizumab (PVZ) has been successfully used in the prevention of this disease and due to the high cost, the Health's Secretary of Minas Gerais (SESMG) provides the product to high-risk groups. Objective: guide pediatricians regarding the prevention of RSV infection with practical guidelines for the prescription of PVZ in MG. Methods: Here are the inclusion criteria for the application of this medication in MG following the guidelines of the Ministry of Health in 2013, as well as the proper procedures for the prescription and supply according to standards of SES-MG. Results and Conclusions: Knowledge about the use of PVZ for the prevention of RSV and about the guidelines for prescription and application of this medication are key to the prevention of bronchiolitis, therefore should be widely disseminated to pediatricians. Thus may occur the reduction of severe cases decreasing the prevalence of sequelae and deaths from this disease.(AU)

La bronquiolitis grave en lactantes menores de seis meses es un factor de riesgo para las sibilancias recurrentes / Severe bronchiolitis in infants under six months is a major risk factor for recurrent wheezing

Introducción y objetivos: diversos factores de riesgo se han asociado con las sibilancias recurrentes después de la bronquiolitis aguda (BA). El objetivo es conocer los factores de riesgo asociados con las sibilancias recurrentes en lactantes (menores de seis meses) previamente sanos hospitalizados con BA en nuestro medio. Material y métodos: estudio observacional, retrospectivo desde enero de 2009 hasta diciembre 2010. Se incluyeron 80 pacientes. Resultados: la media de edad de los niños fue de 69±42 (rango 7-180) días. En el análisis crudo de riesgo relativo (RR) se obtuvo un aumento del RR de sibilancias recurrentes en los pacientes que acudían la guardería (p=0,03; RR: 1,9; intervalo de confianza del 95% [IC 95%]: 1,1 a 3,3), aquellos con hermanos mayores (p=0,03; RR: 2,2; IC 95%: 0,9 a 5,1), pacientes con necesidad de sistemas de alto flujo humidificado y calentado (p=0,05; RR: 2,1; IC 95%: 1,3 a 3,6), ingresados en Cuidados Intensivos (p=0,01; RR: 2,5; IC 95%: 1,06 a 3,08), y con ventilación mecánica (p=0,05; RR: 2,7; IC 95%: 2,0 a 3,7). Tras el análisis multivariante, la asistencia a guardería (odds ratio [OR]: 6,06; IC 95%: 1,4 a 25; p=0,013) y tener hermanos mayores (OR: 4,1; IC 95%: 1,1 a 14,5; p=0,029) resultaron ser factores de riesgo independientes para las sibilancias recurrentes. Conclusiones: la asistencia a la guardería y tener hermanos mayores se asociaron de forma independiente con el diagnóstico de sibilancias recurrentes. Se sugiere que la gravedad de la bronquiolitis es un factor de riesgo notable para desarrollar sibilancias recurrentes un año después de la BA (AU)

Background: several individual and epidemiological risk factors have been associated with recurrent wheezing after acute bronchiolitis (AB). Few research studies focus on very young infants under six months old. Objectives: to find what risk factors are associated with recurrent wheezing in young infants (<6 month-old) hospitalized with moderate to severe acute bronchiolitis (AB) at our setting. Material and methods: a prospective-retrospective, observational study was designed and carried out from January 2009 to December 2011 in a secondary care hospital. Eighty previously healthy patients aged 7-180 days, hospitalized with a first episode of acute moderate AB, were studied. Results: the mean age of infants was 69±42 (range 7-180) days. Crude analysis of relative risk (RR) for recurrent wheezing showed an increased RR in males (p=0.05, RR=1.7 CI 95%: 0.9-3.1), patients in daycare (p=0.03, RR=1.9 CI 95%: 1.1-3.3), with elder siblings (p=0.03, RR=2.2 CI 95%: 0.9-5.1), high-flow therapy (p=0.05, RR=2.1 CI 95%: 1.3-3.6), critical care (p=0.01, RR=2.5 CI 95%: 1.6-3.8), and mechanical ventilation (p=0.05, RR=2.7 CI 95%: 2.0-3.7). After multivariate analysis, daycare attention (OR: 6.06, CI 95%: 1.4-25; p=0.013) and having elder siblings (OR: 4.1, CI 95% 1.1-14.5, p=0.029) were found to be independent risk factors for recurrent wheezing. Conclusions: daycare attendance and having elder siblings were independently associated with recurrent wheezing. We suggest that severity of bronchiolitis (needing PICU, high flow therapy and mechanical ventilation) is a remarkable risk factor for recurrent wheezing one year after AB (AU)

Bronquiolitis aguda / Acute bronchiolitis

No disponible

El suero salino hipertónico nebulizado puede disminuir la duración del ingreso hospitalario en lactantes con bronquiolitis aguda / No disponible

No disponible

Hemoptisis como forma de presentación infrecuente de bronquiolitis obliterante con neumonía organizada (BONO) / Hemoptysis as an uncommon presentation form of bronchiolitis obliterans organizing pneumonia

La hemoptisis es un motivo de consulta poco frecuente en Atención Primaria, pero es importante realizar un correcto diagnóstico diferencial. Las alteraciones inflamatorias y las neoplasias son las causas más frecuentes de hemoptisis en el adulto, mientras que las bronquiectasias, las neumonías y la tuberculosis lo son en los jóvenes. Presentamos el caso de un varón de 43 años, fumador, con un síndrome febril asociado a hemoptisis que permitió establecer el diagnóstico de bronquiolitis obliterante con neumonía organizada (BONO). Se le realizó una primera aproximación diagnóstica en Atención Primaria: anamnesis, exploración física, Mantoux y radiografía de tórax, con resultados normales, y se instauró tratamiento empírico. La falta de respuesta al tratamiento habitual, junto con la persistencia de la fiebre y la hemoptisis, motivó su derivación al hospital. Durante el ingreso la función respiratoria se deterioró progresivamente hasta requerir ventilación mecánica. La biopsia pulmonar permitió establecer el diagnóstico de BONO. El tratamiento con corticoides fue altamente eficaz (AU)

Hemoptysis is an uncommon reason for consulting in Primary Care Out-Patient Clinic (PC). However, it is important to make a correct differential diagnosis. Inflammatory disorders and cancer are the most common causes of hemoptysis in adults while bronchiectasis, pneumonia, and tuberculosis are the most common causes for young people. We present a 43- year-old male, smoker, who had fever and hemoptysis, which made it possible to establish the diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP). The first diagnostic approach was made in PC through an anamnesis, physical examination, Mantoux test and normal chest X-ray and empirical antibiotic treatment was begun. He was referred to the hospital due to lack of response to the usual treatment together with persistent fever and hemoptysis. During his hospitalization, his respiratory function progressively deteriorated and finally required mechanical ventilation. The lung biopsy made it possible to establish the diagnosis of bronchiolitis obliterans organizing pneumonia. Corticosteroid therapy was highly effective (AU)